Eventide Funds are a product of  Eventide Asset Management  

You are now leaving the Eventide Funds website and entering the Eventide Asset Management website.

Continue to Eventide Asset ManagementCancel

Author Archives: Jason Myhre

  1. The Eventide Gilead Fund Ranks Top 1 Percent Within All Mid-Cap Growth Funds for 1 Year, 3 Years, and 5 Years

    Leave a Comment

    BOSTON, MA–(Jul 19, 2013) – The Eventide Gilead Fund’s no-load share class (NASDAQ: ETGLX) was ranked by Morningstar within the top one percent of all U.S. mid-cap growth mutual funds for total returns among 561 funds for the five-year period ending July 08, 2013. July 08, 2013 marks the five-year anniversary for the fund. According to Morningstar, the fund also ranked in the top one percent for the three-year period for total returns out of 637 funds, and the one-year period out of 703 funds.

    During the period, Eventide Gilead Fund was also named Category King by the Wall Street Journal 12 times, the most recent being on June 30, 2013 for ranking within the top 10 performing funds in the mid-cap growth category for one-year performance, based on total returns. According to WSJ, ETGLX ranked #2 in the mid-cap growth equity category, out of 390 funds.

    For the five years ending July 08, 2013, the Eventide Gilead Fund generated an annualized net total return of 15.80%, compared to an annualized total return of 7.57% for the S&P 500 index, an outperformance of 8.23% annualized.

    The following table highlights the Fund’s standard performance since inception:

     As of 6/30/2013 YTD return 1 year return 3 yearannualized return Since inception (7/08/2008) annualized return
    Eventide Gilead Fund* 24.97% 35.61% 24.46% 14.90%
    S&P 500 Total Return Index 13.82% 20.60% 18.45% 7.13%
    Russell Mid-Cap Growth Total Return Index 14.70% 22.88% 19.53% 8.33%

    Expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund’s total annual operating expenses at 1.64% until at least October 31, 2013. Five-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor’s shares, when redeemed, may be worth more or less than their original cost. Please review the fund’s prospectus for more information regarding the fund’s fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

    “We are grateful that the Gilead portfolio has been blessed with these investment results over its first five years,” said Robin John, Eventide CEO.

    Commenting on Eventide’s investment process, Mr. John noted looking for businesses that are attractive in a more comprehensive sense than the typically merely financial:

    “Eventide portfolio companies must have both attractive investment valuations and business models and practices fundamentally oriented towards serving the needs of their stakeholders — customers, employees, and society generally. We believe this broad fundamental analysis contributes to our long-term outperformance potential.”

    The Eventide Gilead Fund also seeks to maintain high internal portfolio diversification and low correlation to the broad market. From co-portfolio manager David Barksdale:

    “In constructing portfolios, we pay close attention to the portfolio’s internal correlation as well as correlation to the broad market. We believe that this helps to improve the Fund’s risk profile as well as the risk profiles of our clients’ portfolios. The R-squared of the Fund since inception is 71.30. One of the reasons for this low R-squared is the portfolio’s overweight in the healthcare sector, particularly in the independent-moving and very exciting small-cap biotechnology space. Small-cap biotech companies’ prices tend to be largely event-driven and are highly affected by clinical trial data releases and the FDA approval process. We believe this is a space where we can continue to find companies that are serving important human needs, have bright financial prospects, and relative independence from broad-market forces.”

    Barksdale also added, “Of course, we also study leading indicators to determine how much macro-risk is appropriate for the portfolio.”

    The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, and based in Boston, MA.

    Morningstar, Inc. All rights reserved. Morningstar is an independent provider of financial information. Morningstar performance rankings are based on total return without sales charge relative to all share classes of mutual funds with similar objectives and determined by Morningstar. Past performance or ranking is not indicative of future results.

    The S&P 500 is an index created by Standard & Poor’s Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.

    R-Squared is a measure of market correlation and is calculated as the square of the correlation of the daily log returns of ETGLX and the S&P 500 Index.

    Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.

    An investor should consider the Fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund’s prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836). You can also obtain a prospectus at www.eventidefunds.com. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.


Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Funds’ ethical values screening criteria could cause them to under-perform similar funds that do not have such screening criteria.

This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Investors should consider a fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.